Highest-materiality recent filing
Exagen reports record FY 2025 revenue of $66.6M, up 20% YoY; guides FY 2026 revenue $70-73M
Full-year 2025 revenue $66.6M (+20% YoY); Q4 2025 revenue $16.6M.
Exagen reports record 2025 revenue $66-67M, up 19-20% YoY; cash at $32M
Q4 2025 revenue $16-17M (17-24% YoY growth); full-year revenue $66-67M (19-20% YoY growth).
Exagen Q3 revenue $17.2M (+38% YoY), record; net loss $7.1M; guides FY rev $65-70M
Revenue $17.2M up 38% YoY; net loss $7.1M vs $5.0M loss last year.
Exagen Q2 revenue $17.2M (+14% YoY); net loss widens to $4.4M; FY guidance $65-70M
Revenue $17.2M, 14% YoY growth; AVISE CTD test volume +7% YoY, +14% QoQ; gross margin 60.4%.
Exagen closes $20.2M public offering at $5.25/share; net proceeds ~$18.6M
Offering of 3,350,000 shares plus full exercise of underwriter's option for 502,500 shares.
Exagen prices public offering of 3.35M shares at $5.25/share for ~$17.6M gross proceeds
3,350,000 shares priced at $5.25; gross proceeds $17.6M; net expected ~$16.2M after expenses.
Exagen Q1 revenue record $15.5M, but net loss widens to $3.8M
Revenue $15.5M (+7.5% YoY); net loss $(3.8)M vs $(3.4)M; adjusted EBITDA $(2.5)M vs $(2.0)M.
Exagen secures up to $75M term loan from Perceptive; $25M funded to retire existing debt
$25M funded at closing used to retire Innovatus debt; net proceeds ~$22.8M after costs.
Exagen reports record FY 2024 revenue of $55.6M; guides Q1 2025 revenue ≥$14.5M
Q4 2024 revenue $13.655M; gross margin 62.1%; FY revenue $55.641M, up from prior year.
Conditional NY State approval for new SLE and RA biomarker assays on AVISE CTD; commercial launch January 2025.
Exagen Q3 revenue $12.5M (-7% YoY); ASP up 26%; net loss improves 37% YTD
Q3 2024 revenue $12.5M, down from $13.4M in Q3 2023, impacted by $1.2M one-time adjustments.
Exagen posts record Q2 revenue $15.1M, raises FY2024 guidance
Record total revenue of $15.1M in Q2 2024, up from $14.1M in Q2 2023.
Exagen appoints Jeffrey Black as CFO effective Sept 1, John Aballi interim CFO
Kamal Adawi terminated as CFO and Corporate Secretary effective August 1, 2024.
Exagen appoints Jeffrey Black as CFO; Kamal Adawi steps down
Jeffrey G. Black named CFO effective Sept 1, 2024; replaces Kamal Adawi.
Exagen Q1 revenue up 28% to $14.4M; raises FY2024 guidance
Revenue $14.4M, +28.4% YoY; gross margin 59.6% vs 47.2% a year ago.
Exagen reports record FY2023 revenue of $52.5M; net loss narrows to $23.7M
Record full-year revenue $52.5M (+10% YoY); Q4 revenue $13.8M (+8% YoY)
On July 25, 2024, Exagen Inc. (the “Company”) appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.
On July 31, 2024, the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of July 31, 2024.
John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi
On July 25, 2024, the Company appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.
replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of August 1, 2024.
the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of August 1, 2024.
Max materiality 0.75 · Median 0.65 · Most common event earnings